Letter regarding “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials”

With great interest, we read the article by Viani et al. [1] recently published in the Green Journal in August 2022. The authors conducted a meta-analysis to synthesize the randomized controlled trials (RCTs) for assessing once-daily versus twice-daily chemoradiation for limited-stage small-cell lung cancer. It is necessary for corresponding clinical decision-makings because meta-analysis could provide more determinate evidence. However, some issues should be addressed to reduce the risk of potential biases and obtain more convincing results.